Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis

Wu,Deyao; Tao,Jun; Ding,Jingjing; Qu,Ping; Lu,Qiang; Zhang,Wei

doi:10.3892/mmr.2012.1199

Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis

Authors:
- Deyao Wu
- Jun Tao
- Jingjing Ding
- Ping Qu
- Qiang Lu
- Wei Zhang
View Affiliations

Affiliations: Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Nanjing, P.R. China, Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, P.R. China, School of Basic Medical Science, Nanjing Medical University, Nanjing, P.R. China, Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Nanjing, P.R. China
Published online on: November 23, 2012 https://doi.org/10.3892/mmr.2012.1199
Pages: 684-688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have suggested that interleukin 11 (IL-11) has roles in human gastric, prostate and bone cancer and endometrial carcinoma. Hence, we evaluated the expression of IL-11 in bladder cancer and the correlation of IL-11 levels and clinicopathological features. The expression of IL-11 in primary human bladder cell culture, human bladder cancer cell lines, transitional cell carcinoma (TCC) and non-cancerous bladder tissues (NATs) were analyzed by western blotting. Enzyme-linked immunosorbent assay (ELISA) for urinary IL-11 was performed to compare the IL-11 levels in healthy subjects and subjects diagnosed with bladder cancer. Our study suggested that the expression of IL-11 in human bladder cancer cell lines and TCC was downregulated compared with primary human bladder cell culture and matched NATs. We also demonstrated reduced urinary levels of IL-11 in subjects with bladder cancer compared with healthy subjects. Furthermore, we revealed that the levels of IL-11 were associated with tumor grade and stage. The results suggested that reduced levels of IL-11 may play an important role in the carcinogenesis and progression of TCC. They also indicated that IL-11 may be a promising predictor for prognosis of TCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL and Ries LA: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 116:544–573. 2010.
3	Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M and Weider J: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 66:4–34. 2005. View Article : Google Scholar : PubMed/NCBI
4	Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 19:429–433. 1992.PubMed/NCBI
5	Bellmunt J and Guix M: New agents for bladder cancer. Ann Oncol. 21(Suppl 7): vii56–58. 2010. View Article : Google Scholar
6	Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK and Bijnens L: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 156:1934–1940. 1996.
7	Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 171:2186–2190; quiz 2435. 2004. View Article : Google Scholar
8	Sengupta S and Blute ML: The management of superficial transitional cell carcinoma of the bladder. Urology. 67:48–54. 2006. View Article : Google Scholar : PubMed/NCBI
9	Dovedi SJ and Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev. 28:355–367. 2009. View Article : Google Scholar : PubMed/NCBI
10	Teramura M, Kobayashi S, Yoshinaga K, Iwabe K and Mizoguchi H: Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol. 38:S99–S102. 1996. View Article : Google Scholar : PubMed/NCBI
11	von Rango U, Alfer J, Kertschanska S, Kemp B, Muller-Newen G, Heinrich PC, Beier HM and Classen-Linke I: Interleukin-11 expression: its significance in eutopic and ectopic human implantation. Mol Hum Reprod. 10:783–792. 2004.PubMed/NCBI
12	McKinley D, Wu Q, Yang-Feng T and Yang YC: Genomic sequence and chromosomal location of human interleukin-11 gene (IL11). Genomics. 13:814–819. 1992. View Article : Google Scholar : PubMed/NCBI
13	Grosfeld JL, Du X and Williams DA: Interleukin-11: its biology and prospects for clinical use. JPEN J Parenter Enteral Nutr. 23:S67–S69. 1999. View Article : Google Scholar : PubMed/NCBI
14	Yap J, Salamonsen LA, Jobling T, Nicholls PK and Dimitriadis E: Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma. Reprod Biol Endocrinol. 8:632010. View Article : Google Scholar : PubMed/NCBI
15	Furuya Y, Nishio R, Junicho A, Nagakawa O and Fuse H: Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer. Int Urol Nephrol. 37:69–71. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sales KJ, Grant V, Cook IH, Maldonado-Perez D, Anderson RA, Williams AR and Jabbour HN: Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol. 176:435–445. 2010. View Article : Google Scholar
17	Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, Uemura T, Yakata Y, Shichijo K, Yamashita S and Sekin I: Expression of interleukin-11 (IL-11) and IL-11 receptor α in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol. 30:825–833. 2007.
18	Trepicchio WL and Dorner AJ: Interleukin-11. A gp130 cytokine. Ann NY Acad Sci. 856:12–21. 1998. View Article : Google Scholar : PubMed/NCBI
19	Du XX and Williams DA: Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood. 83:2023–2030. 1994.PubMed/NCBI
20	Weich NS, Wang A, Fitzgerald M, Neben TY, Donaldson D, Giannotti J, Yetz-Aldape J, Leven RM and Turner KJ: Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood. 90:3893–3902. 1997.
21	Du X, Everett ET, Wang G, Lee WH, Yang Z and Williams DA: Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis. J Cell Physiol. 168:362–372. 1996. View Article : Google Scholar : PubMed/NCBI
22	Musashi M, Yang YC, Paul SR, Clark SC, Sudo T and Ogawa M: Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA. 88:765–769. 1991. View Article : Google Scholar : PubMed/NCBI
23	Musashi M, Clark SC, Sudo T, Urdal DL and Ogawa M: Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood. 78:1448–1451. 1991.PubMed/NCBI
24	Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ and Pragnell IB: Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood. 87:4589–4595. 1996.PubMed/NCBI
25	Yin TG, Schendel P and Yang YC: Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med. 175:211–216. 1992. View Article : Google Scholar : PubMed/NCBI
26	Elias JA, Tang W and Horowitz MC: Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 136:489–498. 1995.PubMed/NCBI
27	Trepicchio WL, Bozza M, Pedneault G and Dorner AJ: Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol. 157:3627–3634. 1996.PubMed/NCBI
28	Kapina MA, Shepelkova GS, Avdeenko VG, Guseva AN, Kondratieva TK, Evstifeev VV and Apt AS: Interleukin-11 drives early lung inflammation during Mycobacterium tuberculosis infection in genetically susceptible mice. PLoS One. 6:e21878
29	Sonis S, Muska A, O’Brien J, Van Vugt A, Langer-Safer P and Keith J: Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol. 31B:261–266. 1995. View Article : Google Scholar : PubMed/NCBI
30	Du X, Liu Q, Yang Z, Orazi A, Rescorla FJ, Grosfeld JL and Williams DA: Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol. 272:G545–G552. 1997.PubMed/NCBI
31	Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT and Pothoulakis C: IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol. 273:G333–G341. 1997.PubMed/NCBI
32	Zheng T, Zhu Z, Wang J, Homer RJ and Elias JA: IL-11: insights in asthma from overexpression transgenic modeling. J Allergy Clin Immunol. 108:489–496. 2001. View Article : Google Scholar : PubMed/NCBI
33	Waxman AB, Einarsson O, Seres T, Knickelbein RG, Warshaw JB, Johnston R, Homer RJ and Elias JA: Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest. 101:1970–1982. 1998.
34	Putoczki T and Ernst M: More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol. 88:1109–1117. 2010. View Article : Google Scholar : PubMed/NCBI
35	Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol. 25:260–268. 2007. View Article : Google Scholar : PubMed/NCBI
36	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer. 3:276–285. 2003. View Article : Google Scholar : PubMed/NCBI
38	Ohshima H, Tatemichi M and Sawa T: Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys. 417:3–11. 2003. View Article : Google Scholar : PubMed/NCBI
39	Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 44:239–267. 2004. View Article : Google Scholar : PubMed/NCBI
40	Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA and Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol. 161:630–634. 1999. View Article : Google Scholar : PubMed/NCBI
41	Egner JR: AJCC Cancer Staging Manual. JAMA. 304:1726–1727. 2010. View Article : Google Scholar
42	Bartsch G, Mitra AP and Cote RJ: Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther. 10:1945–1954. 2010. View Article : Google Scholar : PubMed/NCBI